DMG-ACT: Diffuse Midline Glioma-Adaptive Combinatory Trial. Leading the DMG Center in Zurich, Dr. Mueller and Dr. Nazarian developed the first PNOC working group for DMG and established the DMG-ACT program.

DMG-ACT is a biology driven trial platform conducted through PNOC Global. The working hypothesis of DMG-ACT is that a progressive clinical trial platform that is both adaptive to new data from the laboratory, as well as ongoing correlative studies focused on combinatorial therapies, will allow for more rapid progress in the clinical care of children and families suffering from DMG compared to traditional approaches. Thus, our goal is to test combination treatment approaches in a variety of DMG model systems and multiple laboratories around the world and by leveraging complementary expertise.

DMG-ACT program:

  • Is governed by experts from over 18 institutions across Australia, Europe, and North America
  • Aims to enhance preclinical assessments of potential therapeutic strategies in a variety of DMG models
  • Will assess data reproducibility in laboratories around the world
  • Has built a direct link between clinical research and preclinical research by enhancing correlative assessment
  • Is adaptive to new data generated from the trial as well as from biomedical science investigations, so that new discoveries can be integrated into the care of each patient
  • The DMG-ACT trial will perform extensive correlative studies such as cerebrospinal fluid and tumor tissue analyses for each child enrolled in the trial

DMG-ACT has already led to the development of 2 clinical trial arms